Literature DB >> 22894552

Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases.

Maria A Demontis1, Silva Hilburn, Graham P Taylor.   

Abstract

Human T cell lymphotropic virus type 1 (HTLV-1) proviral load (PVL) in peripheral blood mononuclear cells (PBMCs) is high in patients with adult T cell leukemia/lymphoma or HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in some asymptomatic carriers, but fluctuates. Our objectives were to document ranges of HTLV PVL across a broader spectrum of diseases and tissues, to quantify the normal range of intrapatient PVL variability, and to identify which PVL values and changes deserve further investigation. PVL was measured in 191 patients with HTLV-1-associated diseases and in 211 asymptomatic carriers, using real-time quantitative PCR. The intraassay variability increases as viral load decreases: 8% at high load, 17% at medium load, and 33% at low load. The interassay variability is not different from the intraassay. Mean intrapatient CV is 65% (SD 21) in asymptomatic carriers and 59% (SD 22) in HAM/TSP. PVL values varied widely between individuals, but were relatively constant within individuals. High PVL in cerebrospinal fluid (CSF) and lymph nodes (LN) was associated with disease but 57% of asymptomatic carriers had a PVL greater than 1% in PBMCs. Our results suggest that (1) PVL changes falling outside a coefficient of variation of 100% require more detailed assessment, (2) asymptomatic carriers with PVL higher than 10% should undergo more frequent clinical and laboratory monitoring, and (3) HTLV-1 PVL in blood and tissue is helpful in the diagnosis and monitoring of HTLV-1 infection.

Entities:  

Mesh:

Year:  2012        PMID: 22894552     DOI: 10.1089/AID.2012.0132

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  45 in total

1.  Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease?

Authors:  Marina Lobato Martins; Jacqueline Cronemberger Guimarães; João Gabriel Ribas; Luiz Cláudio Ferreira Romanelli; Anna Bárbara de Freitas Carneiro-Proietti
Journal:  J Neurovirol       Date:  2016-09-27       Impact factor: 2.643

2.  Update on Neurological Manifestations of HTLV-1 Infection.

Authors:  Abelardo Q-C Araujo
Journal:  Curr Infect Dis Rep       Date:  2015-02       Impact factor: 3.725

3.  Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations.

Authors:  Giovanna S Brunetto; Raya Massoud; Emily C Leibovitch; Breanna Caruso; Kory Johnson; Joan Ohayon; Kaylan Fenton; Irene Cortese; Steven Jacobson
Journal:  J Neurovirol       Date:  2014-04-30       Impact factor: 2.643

4.  Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma.

Authors:  Lucy B Cook; Aileen G Rowan; Maria A Demontis; Sophie Sagawe; Nicolas A Gillet; Anat Melamed; Claire Greiller; Aviva Witkover; Charles R M Bangham; Graham P Taylor
Journal:  Int J Hematol       Date:  2017-10-31       Impact factor: 2.490

5.  Utility of HTLV proviral load quantification in diagnosis of HTLV-1-associated myelopathy requires international standardization.

Authors:  Maria Fernanda Rios Grassi; Viviana Nilla Olavarria; Ramon de Almeida Kruschewsky; Yoshihisa Yamano; Steven Jacobson; Graham P Taylor; Fabiola Martin; Bernardo Galvão-Castro
Journal:  J Clin Virol       Date:  2013-09-13       Impact factor: 3.168

6.  HTLV-1 proviral load in cerebrospinal fluid may not be a good marker to differentiate asymptomatic carriers with high proviral load in blood from HAM/TSP patients.

Authors:  Marina Lobato Martins; Anna Bárbara de Freitas Carneiro-Proietti; Rodrigo Nicolato; Débora Marques de Miranda; Luiz Cláudio Ferreira Romanelli
Journal:  J Neurovirol       Date:  2018-03-27       Impact factor: 2.643

7.  Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans.

Authors:  Maria Fernanda de Castro-Amarante; Cynthia A Pise-Masison; Katherine McKinnon; Robyn Washington Parks; Veronica Galli; Maria Omsland; Vibeke Andresen; Raya Massoud; Giovanna Brunetto; Breanna Caruso; David Venzon; Steven Jacobson; Genoveffa Franchini
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

8.  Simian T-lymphotropic Virus-associated lymphoma in 2 naturally infected baboons: T-cell clonal expansion and immune response during tumor development.

Authors:  Jean M d'Offay; Richard Eberle; Roman F Wolf; Stanley D Kosanke; Kelly R Doocy; Sahlu Ayalew; Keith G Mansfeild; Gary L White
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

9.  HIV and HTLV-1 coinfection: the need to initiate antiretroviral therapy.

Authors:  Eduardo Ticona; Moises A Huaman; Omar Yanque; Joseph R Zunt
Journal:  J Int Assoc Provid AIDS Care       Date:  2013 Nov-Dec

10.  Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab.

Authors:  Lucy B M Cook; Maria Antonietta Demontis; Sophie Sagawe; Aviva Witkover; Anat Melamed; Jocelyn Turpin; Richard Dillon; Jana Haddow; Alexandra J Marks; Charles R M Bangham; Paul Fields; Graham P Taylor; Aileen G Rowan
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.